Cargando…

Dose Regimen Rationale for Panitumumab in Cancer Patients: To Be Based on Body Weight or Not

INTRODUCTION: Body weight can affect exposure, safety and efficacy of antibody-based therapies; sometimes these effects may not be clinically relevant. Panitumumab is approved for wild-type RAS metastatic colorectal cancer, using a body weight–based dosing regimen. Recently, a report cited fixed-dos...

Descripción completa

Detalles Bibliográficos
Autores principales: Liao, Michael Z, Berkhout, Marloes, Prenen, Hans, Dutta, Sandeep, Upreti, Vijay V
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7406372/
https://www.ncbi.nlm.nih.gov/pubmed/32801947
http://dx.doi.org/10.2147/CPAA.S262949
_version_ 1783567405483556864
author Liao, Michael Z
Berkhout, Marloes
Prenen, Hans
Dutta, Sandeep
Upreti, Vijay V
author_facet Liao, Michael Z
Berkhout, Marloes
Prenen, Hans
Dutta, Sandeep
Upreti, Vijay V
author_sort Liao, Michael Z
collection PubMed
description INTRODUCTION: Body weight can affect exposure, safety and efficacy of antibody-based therapies; sometimes these effects may not be clinically relevant. Panitumumab is approved for wild-type RAS metastatic colorectal cancer, using a body weight–based dosing regimen. Recently, a report cited fixed-dose usage of panitumumab, rather than approved body weight–based dosing. The current work evaluates optimal dosing regimen scientifically based on clinical data, modeling and simulation. Herein, we assessed the effect of fixed and body weight–based dosing on panitumumab pharmacokinetics to determine which approach resulted in the least interpatient pharmacokinetic variability. PATIENTS AND METHODS: From the Vectibix program, 352 patients enrolled in three studies were evaluated; they had received panitumumab (body weight–based dose: 6 mg/kg every 2 weeks) and had pharmacokinetic (maximum serum [C(max]) and trough [C(min)] concentrations) and body weight data available. Additionally, concentration-time profiles at fixed (480 mg) and body weight–based doses (6 mg/kg) were simulated using a population pharmacokinetics model developed from 1200 patients. RESULTS: After administration of panitumumab 6 mg/kg, C(max) and C(min) increased with increasing body weight; the mean C(max) and C(min) for patients weighing <65 kg (lower quartile) were 23% and 30% lower, respectively, than for those weighing >88 kg (upper quartile). The simulated area under the concentration–time curve (AUC) data also indicated that overall panitumumab exposure increased with increasing body weight for the body weight–based regimen. When AUC was simulated for a fixed dose (480 mg), the opposite effect was observed. Over the range of body weights, interpatient variability in simulated AUC was lower for the weight-based dose (29%) than for the fixed dose (34%). CONCLUSION: Results demonstrate that the weight-based dose (6 mg/kg) reduced variability in panitumumab exposure across the range of body weights compared with the fixed-dose approach, indicating that a body weight–based approach is the recommended patient dosing strategy.
format Online
Article
Text
id pubmed-7406372
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-74063722020-08-13 Dose Regimen Rationale for Panitumumab in Cancer Patients: To Be Based on Body Weight or Not Liao, Michael Z Berkhout, Marloes Prenen, Hans Dutta, Sandeep Upreti, Vijay V Clin Pharmacol Original Research INTRODUCTION: Body weight can affect exposure, safety and efficacy of antibody-based therapies; sometimes these effects may not be clinically relevant. Panitumumab is approved for wild-type RAS metastatic colorectal cancer, using a body weight–based dosing regimen. Recently, a report cited fixed-dose usage of panitumumab, rather than approved body weight–based dosing. The current work evaluates optimal dosing regimen scientifically based on clinical data, modeling and simulation. Herein, we assessed the effect of fixed and body weight–based dosing on panitumumab pharmacokinetics to determine which approach resulted in the least interpatient pharmacokinetic variability. PATIENTS AND METHODS: From the Vectibix program, 352 patients enrolled in three studies were evaluated; they had received panitumumab (body weight–based dose: 6 mg/kg every 2 weeks) and had pharmacokinetic (maximum serum [C(max]) and trough [C(min)] concentrations) and body weight data available. Additionally, concentration-time profiles at fixed (480 mg) and body weight–based doses (6 mg/kg) were simulated using a population pharmacokinetics model developed from 1200 patients. RESULTS: After administration of panitumumab 6 mg/kg, C(max) and C(min) increased with increasing body weight; the mean C(max) and C(min) for patients weighing <65 kg (lower quartile) were 23% and 30% lower, respectively, than for those weighing >88 kg (upper quartile). The simulated area under the concentration–time curve (AUC) data also indicated that overall panitumumab exposure increased with increasing body weight for the body weight–based regimen. When AUC was simulated for a fixed dose (480 mg), the opposite effect was observed. Over the range of body weights, interpatient variability in simulated AUC was lower for the weight-based dose (29%) than for the fixed dose (34%). CONCLUSION: Results demonstrate that the weight-based dose (6 mg/kg) reduced variability in panitumumab exposure across the range of body weights compared with the fixed-dose approach, indicating that a body weight–based approach is the recommended patient dosing strategy. Dove 2020-07-31 /pmc/articles/PMC7406372/ /pubmed/32801947 http://dx.doi.org/10.2147/CPAA.S262949 Text en © 2020 Liao et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Liao, Michael Z
Berkhout, Marloes
Prenen, Hans
Dutta, Sandeep
Upreti, Vijay V
Dose Regimen Rationale for Panitumumab in Cancer Patients: To Be Based on Body Weight or Not
title Dose Regimen Rationale for Panitumumab in Cancer Patients: To Be Based on Body Weight or Not
title_full Dose Regimen Rationale for Panitumumab in Cancer Patients: To Be Based on Body Weight or Not
title_fullStr Dose Regimen Rationale for Panitumumab in Cancer Patients: To Be Based on Body Weight or Not
title_full_unstemmed Dose Regimen Rationale for Panitumumab in Cancer Patients: To Be Based on Body Weight or Not
title_short Dose Regimen Rationale for Panitumumab in Cancer Patients: To Be Based on Body Weight or Not
title_sort dose regimen rationale for panitumumab in cancer patients: to be based on body weight or not
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7406372/
https://www.ncbi.nlm.nih.gov/pubmed/32801947
http://dx.doi.org/10.2147/CPAA.S262949
work_keys_str_mv AT liaomichaelz doseregimenrationaleforpanitumumabincancerpatientstobebasedonbodyweightornot
AT berkhoutmarloes doseregimenrationaleforpanitumumabincancerpatientstobebasedonbodyweightornot
AT prenenhans doseregimenrationaleforpanitumumabincancerpatientstobebasedonbodyweightornot
AT duttasandeep doseregimenrationaleforpanitumumabincancerpatientstobebasedonbodyweightornot
AT upretivijayv doseregimenrationaleforpanitumumabincancerpatientstobebasedonbodyweightornot